Rio de Janeiro, Brazil - Shanghai MicroPort Medical (Group) Co ("MicroPort®") recently attended the Society of Latin American Cardiology Intervention 2016 ("SOLACI 2016") held from June 8 to June 10 with about 2,000 experts from South America in attendance. MicroPort® hosted a dinner party to celebrate the market launch of Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®") in Brazil, and rebroadcasted a surgery using Firebird2® Rapamycin-Eluting Coronary CoCr Stent ("Firebird2®").
MicroPort®'s in-house developed Firebird® Rapamycin-Eluting Coronary Stent ("Firebird®") and Firebird2® have been sold in South America for nearly 10 years and gained good market feedback. Its third-generation drug-eluting stent Firehawk® was recently approved for market launch in Brazil. Thus, on the occasion of SOLACI 2016, MicroPort® hosted a dinner party themed on "Firehawk®, Let's Fly." Jonathan Chen, MicroPort® Senior Vice President of International Operations and Investor Relations, delivered the opening speech. Argentine prominent intervention expert Dr. Alfredo Rodriguez, who is from Sanatorio Otamendi Hospital, introduced the latest development of Firehawk® TARGET Serial Clinical Trials to people in attendance. Dr. Nogueira Paes of Brazil-based Hospital Prontocardio noted, TARGET Clinical Trials have achieved satisfactory outcome. In addition, Dr. Rodriguez said he will participate in the prospective, multi-center, parallel, randomized and controlled trial Definition II, organized by Professor Shaoliang Chen, Vice President of Nanjing First Hospital.
On June 9, a surgery using Firebird2® to treat left main coronary artery disease was rebroadcasted during SOLACI 2016. In the surgery, Dr. Frenando Mendes Santanna successfully implanted a Firebird2® into a patient, demonstrating Firebird2®'s safety and efficacy in treating complex lesion, which was well received by the audience.
During the congress, MicroPort® booth attracted wide attention from the attendees. SOLACI 2016 provided a platform for South American experts and distributors to gain deeper understanding in MicroPort®'s innovative products and its capabilities of sustained innovation, paving the way for MicroPort® to further expand the South American market to serve more overseas patients.
This website may store cookies on your browser. Cookies are mostly used to make the website work as you expect it to. No cookie will directly identify you, but it can give you a more personalized browsing experience.
MicroPort respects your privacy rights, so you can block some types of cookies. Technically non-essential cookies and tracking mechanisms, that enable us to provide you with customized offers (marketing cookies), are only used if you have given prior consent to such use.
By clicking “Save”, only the cookies you selected will be used. You can withdraw the consent that you granted here at any time by going to Cookies Settings.